Clinical significance of anti-rheumatoid arthritis 33 antibody in patients with systemic lupus erythematosus

Lu, Wen-Yi; Hong, Xiao-Ping; Xie, Jing-Yi; Liu, Cui-Lian; Chen, Cui-Hong; Sun, Bao-Dong; Liu, Dong-Zhou; Chen, Yu-Lan

2023-04-01

10.1177/10815589221150643

JOURNAL OF INVESTIGATIVE MEDICINE   影响因子和分区

1081-5589

1708-8267

Although anti-rheumatoid arthritis (RA) 33 antibodies have been reported to be present in various connective tissue diseases (CTDs), the clinical significance of anti-RA33 in CTDs is still obscure. This study was performed to explore the clinical significance of anti-RA33 in CTDs, especially systemic lupus erythematosus (SLE). A total of 565 patients with positive anti-nuclear antibodies who had been tested for anti-RA33 were included in this study and were further classified into RA33-positive and RA33-negative groups. The association between anti-RA33 and the clinical features of CTDs was examined. Receiver operating characteristic (ROC) analysis was performed to explore the diagnostic value of anti-RA33 in SLE and SLE-related organ involvement. The results showed that SLE was the most common disease in CTD patients positive for anti-RA33 (48.8%). Compared with the RA33-negative group, higher proportions of SLE-associated antibodies and SLE patients with a high disease activity as well as lower levels of serum complement components were observed in the RA33-positive group (all p < 0.05). Furthermore, CTD patients with positive anti-RA33 were more likely to suffer from mucocutaneous and hematological involvement as well as interstitial lung disease (all p < 0.05). ROC analysis revealed an area under the curve value of 0.634 (95% confidence interval: 0.587-0.681) for anti-RA33 in the diagnosis of SLE, with a specificity and sensitivity of 92.9% and 13.5%, respectively. Taken together, this study reveals a significant association between anti-RA33 and the clinical features of CTDs, especially SLE, indicating a potential clinical significance of anti-RA33 in the management of SLE.

Anti-rheumatoid arthritis 33 antibodies systemic lupus erythematosus connective tissue diseases organ involvement diagnostic value

SCI

英语

其他

Shenzhen Science and Technology[JCYJ20190807144418845] ; National Natural Science Foundation of China[81971464] ; National Key Research and Development[2019YFC0840600]

General & Internal Medicine ; Research & Experimental Medicine

Medicine, General & Internal ; Medicine, Research & Experimental

WOS:000956447300014

SAGE PUBLICATIONS LTD

CLINICAL MEDICINE

Web of Science

1.Jinan Univ, Shenzhen Peoples Hosp, Dept Rheumatol & Immunol, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China

Lu, Wen-Yi,Hong, Xiao-Ping,Xie, Jing-Yi,et al. Clinical significance of anti-rheumatoid arthritis 33 antibody in patients with systemic lupus erythematosus[J]. JOURNAL OF INVESTIGATIVE MEDICINE,2023,71(4).

Lu, Wen-Yi.,Hong, Xiao-Ping.,Xie, Jing-Yi.,Liu, Cui-Lian.,Chen, Cui-Hong.,...&Chen, Yu-Lan.(2023).Clinical significance of anti-rheumatoid arthritis 33 antibody in patients with systemic lupus erythematosus.JOURNAL OF INVESTIGATIVE MEDICINE,71(4).

Lu, Wen-Yi,et al."Clinical significance of anti-rheumatoid arthritis 33 antibody in patients with systemic lupus erythematosus".JOURNAL OF INVESTIGATIVE MEDICINE 71.4(2023).